# US 2003/0211127 A1 · Controlled dissolution crosslinked prote in crystals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211127 A1
- Document ID: US20030211127A1
- Status: Published application
- Kind: A1
- Application number: 10/337,061
- Filed: 2003-01-02
- Published: 2003-11-13
- Earliest claimed: 1997-04-11
- Inventors: Alexey L. Margolin; Rose A. Persichetti; Nancy L. St. Clair; Nazer K. Khalaf; Bhami C. Shenoy
- Web page: https://patentgrep.com/patent/US20030211127A1

## CPC

- C12N 9/54: bacteria being Bacillus
- A23K 20/147: Polymeric derivatives, e.g. peptides or proteins
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61P 31/12: Antivirals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 5/02: Preparations for cleaning the hair
- A61Q 19/00: Preparations for care of the skin
- C07K 14/765: Serum albumin, e.g. HSA
- C11D 3/3719: {Polyamides or polyimides}
- C11D 3/38: Products with no well-defined composition {, e.g. natural products}
- C11D 3/386: Preparations containing enzymes {, e.g. protease or amylase}
- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- C12N 9/92: Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 11/00: Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12Y 304/21062: Subtilisin (3.4.21.62)
- C12Y 304/24027: Thermolysin (3.4.24.27)
- C12Y 503/01005: Xylose isomerase (5.3.1.5)
- C30B 29/58: Macromolecular compounds
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- Y10S 530/81: Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C11D: DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C12Y: ENZYMES
- C30B: SINGLE-CRYSTAL GROWTH (by using ultra-high pressure, e.g. for the formation of diamonds, B01J3/06); UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL (zone-refining of metals or alloys C22B); PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (casting of metals, casting of other substances by the same processes or devices B22D; working of plastics B29; modifying the physical structure of metals or alloys C21D, C22F); SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (for producing semiconductor devices or parts thereof H10); APPARATUS THEREFOR
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in oxidation-reduction potential of the solution, change in the incident radiation, change in transition metal concentration, change in flouride concentration, change in free radical concentration, change in metal chelater concentration, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate. This invention also provides methods for producing such crosslinked protein crystals, methods using them for protein delivery and methods using them in cleaning agents, including detergents, pharmaceutical compositions, vaccines, personal care compositions, including cosmetics, veterinary compositions, foods, feeds, diagnostics and formulations for decontamination.

## Claims

### Claim 1

A crosslinked protein crystal, said protein crystal being capable of change from insoluble and stable form to soluble and active form and releasing between 0.1% and 100% of crystalline material as soluble protein per day upon a change in the environment surrounding said crystal, said change being selected from the group consisting of: change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in shear force acting upon the crystal and combinations thereof.

### Claim 2 (depends on 1)

The crosslinked protein crystal according to claim 1, wherein said change from concentrate to dilute form comprises a change in solute concentration.

### Claim 3 (depends on 2)

The crosslinked protein crystal according to claim 2, wherein said change in solute concentration comprises an increase or decrease in salt concentration.

### Claim 4 (depends on 3)

The crosslinked protein crystal according to claim 3, wherein said change in solute concentration comprises a decrease in salt concentration.

### Claim 5 (depends on 2)

The crosslinked protein crystal according to claim 2, wherein said change in solute concentration comprises an increase or decrease in water concentration.

### Claim 6 (depends on 5)

The crosslinked protein crystal according to claim 5, wherein said change in solute concentration comprises an increase in water concentration.

### Claim 7 (depends on 2)

The crosslinked protein crystal according to claim 2, wherein said change in solute concentration comprises an increase or decrease in organic solvent concentration.

### Claim 8 (depends on 2)

The crosslinked protein crystal according to claim 2, wherein said change in solute concentration comprises a decrease in detergent concentration.

### Claim 9 (depends on 2)

The crosslinked protein crystal according to claim 2, wherein said change in solute concentration comprises a decrease in protein concentration.

### Claim 10 (depends on 1)

The crosslinked protein crystal according to claim 1, wherein said change from concentrate to dilute form comprises a change in concentration of all solutes from about 2-fold to about 10,000-fold.

### Claim 11 (depends on 10)

The crosslinked protein crystal according to claim 10, wherein said change from concentrate to dilute form comprises a change in concentration of all solutes from about 2-fold to about 700-fold.

### Claim 12 (depends on 1)

The crosslinked protein crystal according to claim 1, wherein said change in pH comprises a change from acidic pH to basic pH.

### Claim 13 (depends on 1)

The crosslinked protein crystal according to claim 1, wherein said change in pH comprises a change from basic pH to acidic pH.

### Claim 14 (depends on 1)

The crosslinked protein crystal according to claim 1, wherein said change in temperature comprises an increase or decrease in temperature.

### Claim 15 (depends on 14)

The crosslinked protein crystal according to claim 14, wherein said change in temperature is an increase in temperature from a low temperature between about 0° C. and about 20° C. to a high temperature between about 25° C. and about 70° C.

### Claim 16 (depends on 1)

The crosslinked protein crystal according to claim 1, wherein said active form of said protein is a form which is active against macromolecular substrates.

### Claim 17

A crosslinked protein crystal, said protein crystal having a half-life of activity under storage conditions which is greater than at least 2 times that of the soluble form of the protein that is crystallized to form said crystal that is crosslinked and activity similar to that of the soluble form of the protein under conditions of use and which releases between 0.1% and 100% of crystalline material as soluble protein per day.

### Claim 18

A crosslinked protein crystal, said protein crystal being capable of releasing its protein activity at a controlled rate of between 0.1% and 100% of crystalline material as soluble protein per day upon exposure to a change in the environment surrounding said crystal, said change being selected from the group consisting of change in pH, change in solute concentration, change in temperature, change in chemical composition, change in shear force acting upon the crystals and combinations thereof.

### Claim 19

A crosslinked protein crystal, said protein crystal having a 5 to 10 fold higher protein activity for any one of a macromolecular substrate, a biphasic substrate or a small molecule substrate, as compared with the soluble form of the protein that is crystallized to form the crystals that are crosslinked and releasing between 0.1% and 100% of crystalline material as soluble protein per day.

### Claim 20

A crosslinked protein crystal, said protein crystal having a 2 to 3 fold higher protein activity for any one of a macromolecular substrate, a biphasic substrate or a small molecule substrate as compared with the soluble form of the protein that is crystallized to form the crystals that are crosslinked and releasing between 0.1% and 100%c of crystalline material as soluble protein per day.

### Claim 21

A crosslinked protein crystal, said protein crystal having at least 2 times higher protein activity for a macromolecular substrate, a biphasic substrate or a small molecule substrate as compared with the soluble form of the enzyme that is crystallized to form the crystals that are crosslinked and releasing between 0.1% and 100% of crystalline material as soluble protein per day.

### Claim 22

A crosslinked lipase crystal, said lipase crystal having a 5 to 10 fold higher enzyme activity for hydrolysis of a biphasic olive oil substrate as compared with the soluble form of the lipase that is crystallized to form the crystals that are crosslinked.

### Claim 23 (depends on 22)

The crosslinked lipase crystal according to claim 22, said lipase crystal having a 2 to 3 fold higher enzyme activity for hydrolysis of a biphasic olive oil substrate as compared with the soluble form of the lipase that is crystallized to form the crystals that are crosslinked.

### Claim 24 (depends on 23)

The crosslinked lipase crystal according to claim 23, said lipase crystal having at least 2 times higher protein activity for hydrolysis of a biphasic olive oil substrate as compared with the soluble form of the lipase that is crystallized to form the crystals that are crosslinked.

### Claim 25 (depends on 22, 23, 24)

The crosslinked protein crystal according to any one of claims 22, 23 or 24, wherein said protein is crosslinked by sulfosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio) toluamido] hexanoate (Sulfo-LC-SMPT).

### Claim 26 (depends on 22, 23, 24)

The crosslinked protein crystal according to any one of claims 22, 23 or 24, wherein said protein is crosslinked by 1-ethyl-3-[3-dimethylaminoproplyl]carbodiimide hydrochloride (EDC).

### Claim 27 (depends on 22, 23, 24)

The crosslinked lipase crystal according to any one of claims 22, 23 or 24, wherein said lipase is crosslinked by sulfosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio) toluamido] hexanoate (Sulfo-LC-SMPT).

### Claim 28 (depends on 22, 23, 24)

The crosslinked lipase crystal according to any one of claims 22, 23 or 24, wherein said lipase is crosslinked by 1-ethyl-3-[3-dimethylaminoproplyl] carbodiimide hydrochloride (EDC).

### Claim 29 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, wherein said protein is crosslinked by a homobifunctional crosslinker.

### Claim 30 (depends on 1, 17, 18, 19, 20)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20, or 21, wherein said protein is crosslinked by a heterobifunctional crosslinker.

### Claim 31 (depends on 18)

The crosslinked protein crystal according to claim 18, wherein said controlled rate of releasing protein activity is determined by a factor selected from the group consisting of: the degree of crosslinking of said crosslinked protein crystal, the length of time of exposure of protein crystal to the crosslinker, the amino acids residues involved in the crosslinks, whether the crosslinker is homobifunctional or heterobifunctional, the rate of addition of the crosslinking agent to said protein crystal, the nature of the crosslinker, the chain length of the crosslinker, the surface area of said crosslinked protein crystal, the size of said crosslinked protein crystal, the shape of said crosslinked protein crystal and combinations thereof.

### Claim 32 (depends on 18)

The crosslinked protein crystal according to claim 18, wherein said crystal has a protein activity release rate of between about 0.1% per day and about 100% per day.

### Claim 33 (depends on 18)

The crosslinked protein crystal according to claim 18, wherein said crystal has a protein activity release rate between about 0.01% per hour and about 100% per hour.

### Claim 34 (depends on 18)

The crosslinked protein crystal according to claim 18, wherein said crystal has a protein activity release rate between about 1% per minute and about 50% per minute.

### Claim 35 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, said protein crystal being substantially insoluble and stable in a composition under storage conditions and substantially soluble and active under conditions of use of said composition.

### Claim 36 (depends on 35)

The crosslinked protein crystal according to claim 35, wherein said composition is selected from the group consisting of cleaning agents, detergents, personal care compositions, cosmetics, pharmaceuticals, veterinary compounds, vaccines, foods, feeds, diagnostics and formulations for decontamination.

### Claim 37 (depends on 36)

The crosslinked protein crystal according to claim 36, wherein said detergent is selected from the group consisting of powdered detergents, liquid detergents, bleaches, household cleaners, hard surface cleaners, industrial cleaners, carpet shampoos and upholstery shampoos.

### Claim 38 (depends on 36)

The crosslinked protein crystal according to claim 36, wherein said cosmetic is selected from the group consisting of creams, emulsions, lotions, foams, washes, gels, compacts, mousses, sunscreens, slurries, powders, sprays, foams, pastes, ointments, salves, balms, shampoos, and drops.

### Claim 39 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, wherein said protein is an enzyme.

### Claim 40 (depends on 39)

The crosslinked protein crystal according to claim 39, wherein said enzyme is selected from the group consisting of hydrolases, isomerases, lyases, ligases, transferases and oxidoreductases.

### Claim 41 (depends on 40)

The crosslinked protein crystal according to claim 40, wherein said enzyme is selected from the group consisting of proteases, amylases, cellulases, lipases and oxidases.

### Claim 42 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, wherein said protein is selected from the group consisting of therapeutic proteins, cleaning agent proteins, personal care proteins, veterinary proteins, food proteins, feed proteins, diagnostic proteins and decontamination proteins.

### Claim 43 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, wherein said protein is selected from the group consisting of hormones, antibodies, inhibitors, growth factors, trophic factors, cytokines, lymphokines, growth hormones, nerve growth hormones, bone morphogenic proteins and toxoids.

### Claim 44 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, wherein said protein is selected from the group consisting of insulin, amylin, erythropoietin, Factor VIII, TPA, dornase-α, α-1-antitripsin, urease, fertility hormones, FSH, LSH, postridical hormones, tetanus toxoid and diptheria toxoid.

### Claim 45 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, said crystal having a longest dimension of between about 0.01 μm and about 500 μm.

### Claim 46 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, said crystal having a longest dimension of between about 0.1 μm and about 50 μm.

### Claim 47 (depends on 1, 17, 18, 19, 20, 21)

The crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, said crystal having a shape selected from the group consisting of: spheres, needles, rods, plates, rhomboids, cubes, bipryamids and prisms.

### Claim 48 (depends on 1, 17, 18, 19, 20, 21)

A composition comprising a crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, said composition being selected from the group consisting of cleaning agents, detergents, personal care compositions, cosmetics, pharmaceuticals, veterinary compounds, vaccines, foods, feeds, diagnostics and formulations for decontamination.

### Claim 49 (depends on 48)

The composition according to claim 48, wherein said detergent is selected from the group consisting of powdered detergents, liquid detergents, bleaches, household cleaners, hard surface cleaners, industrial cleaners, carpet shampoos and upholstery shampoos.

### Claim 50 (depends on 48)

The composition according to claim 48, wherein said cosmetic is selected from the group consisting of creams, emulsions, lotions, foams, washes, gels, compacts, slurries, powders, sprays, foams, pastes, ointments, salves, balms, shampoos, sunscreens and drops.

### Claim 51 (depends on 1, 17, 18, 19, 20)

A protein delivery system, said system comprising crosslinked protein crystals according to any one of claims 1, 17, 18, 19, 20, or 21.

### Claim 52 (depends on 51)

The protein delivery system according to claim 51, wherein said protein is selected from the group consisting of: detergent enzymes, cosmetic proteins, pharmaceutical proteins, agricultural proteins, vaccine proteins and decontamination proteins.

### Claim 53 (depends on 52)

The protein delivery system according to claim 52, said protein delivery system being a microparticulate protein delivery system.

### Claim 54 (depends on 53)

The protein delivery system according to claim 53, wherein said microparticulate protein delivery system comprises crosslinked protein crystals having a longest dimension between about 0.01 μm and about 500 μm.

### Claim 55 (depends on 54)

The protein delivery system according to claim 54, wherein said microparticulate protein delivery system comprises crosslinked protein crystals having a longest dimension of between about 0.1 μm and about 50 μm.

### Claim 56 (depends on 53)

The protein delivery system according to claim 53, wherein said microparticulate protein delivery system comprises crosslinked protein crystals having a shape selected from the group consisting of: spheres, needles, rods, plates, rhomboids, cubes, bipryamids and prisms.

### Claim 57 (depends on 1, 17, 18, 19, 20)

A detergent formulation comprising a crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20, or 21.

### Claim 58 (depends on 1, 17, 18, 19, 20, 21)

A controlled release formulation comprising a crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21.

### Claim 59 (depends on 1, 17, 18, 19, 20, 21)

A pharmaceutical controlled release formulation comprising a crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21.

### Claim 60

A pharmaceutical controlled release formulation comprising a crosslinked protein crystal, said crystal being substantially insoluble under storage conditions and capable of releasing its protein activity in vivo at a controlled rate of between 0.1% and 100% of crystalline material as soluble protein per day.

### Claim 61 (depends on 59)

The pharmaceutical controlled release formulation according to claim 59, said pharmaceutical being capable of administration by parenteral or non-parenteral routes.

### Claim 62 (depends on 61)

The pharmaceutical controlled release formulation according to claim 61, said pharmaceutical being capable of administration by oral, pulmonary, nasal, aural, anal, dermal, ocular, intravenous, intramuscular, intraarterial, intraperitoneal, mucosal, sublingual, subcutaneous or intracranial route.

### Claim 63 (depends on 59)

The pharmaceutical controlled release formulation according to claim 59, wherein said pharmaceutical is capable of administration by oral route and said crosslinked protein crystal is substantially insoluble under gastric pH conditions and substantially soluble under small intestine pH conditions.

### Claim 64 (depends on 1, 17, 18, 19, 20, 21)

A vaccine comprising a crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21.

### Claim 65 (depends on 1, 17, 18, 19, 20, 21)

A formulation comprising a crosslinked protein crystal according to any one of claims 1, 17, 18, 19, 20 or 21, said formulation being selected from the group consisting of tablets, liposomes, granules, spheres, microspheres, microparticles and capsules.

### Claim 66

A method for producing crosslinked protein crystals comprising the step of reacting protein crystals with a first crosslinking agent, or a first crosslinking agent and at least a second crosslinking agent, under conditions sufficient to induce crosslinking of said crystals to the extent that the resulting crosslinked crystals are characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in their environment, and to release between 0.1% and 100% of crystalline material as soluble protein per day, wherein said change is selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in shear force acting upon the crystals and combinations thereof.

### Claim 67

A method for producing crosslinked protein crystals comprising the step of reacting protein crystals with a first crosslinking agent, or a first crosslinking agent and at least a second crosslinking agent, under conditions sufficient to induce crosslinking of said crystals to the extent that the resulting crosslinked crystals are characterized by a half-life of activity under storage conditions which is greater than at least 2 times that of the soluble form of the protein that is crystallized to form said crystals that are crosslinked and activity similar to that of the soluble form of the protein and which release between 0.1% and 100% of crystalline material as soluble protein per day under conditions of use.

### Claim 68

A method for producing crosslinked protein crystals comprising the step of reacting protein crystals with a first crosslinking agent, or a first crosslinking agent and at least a second crosslinking agent, under conditions sufficient to induce crosslinking of said crystals to the extent that the resulting crosslinked crystals are characterized by being capable of releasing their protein activity at a controlled rate of between 0.1% and 100% of crystalline material as soluble protein per day upon exposure to a change in their environment, said change being selected from the group consisting of change in pH, change in soluble concentration, change in temperature, change in chemical composition, change in shear force acting upon the crystals and combinations thereof.

### Claim 69 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, comprising the step of reacting said protein crystals with said first crosslinking agent and said at least a second crosslinking agent at the same time or in sequence.

### Claim 70 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein, prior to reacting protein crystals with said crosslinking agent, said method further comprises the step of crystallizing said protein.

### Claim 71 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein the conditions sufficient to induce crosslinking are dependent upon a factor selected from the group consisting of: the degree of crosslinking of said crosslinked protein crystals, the length of time of exposure of protein crystals to the crosslinking agent, the rate of addition of the crosslinking agent to said protein crystal, the nature of the crosslinker, the chain length of the crosslinker, the surface area of said crosslinked protein crystals, the size of said crosslinked protein crystals, the shape of said crosslinked protein crystals and combinations thereof.

### Claim 72 (depends on 68)

The method for producing crosslinked protein crystals according to claim 68, wherein said controlled rate of releasing protein activity is determined by a factor selected from the group consisting of: the degree of crosslinking of said crosslinked protein crystals, the length of time of exposure of protein crystals to the crosslinking agent, the rate of addition of the crosslinking agent to said protein crystals, the nature of the crosslinker, the chain length of the crosslinker, the surface area of said crosslinked protein crystals, the size of said crosslinked protein crystals, the shape of said crosslinked protein crystals and combinations thereof.

### Claim 73 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is a multifunctional crosslinking agent.

### Claim 74 (depends on 73)

The method for producing crosslinked protein crystals according to claim 73, wherein said crosslinking agent is a bifunctional crosslinking agent.

### Claim 75 (depends on 73)

The method for producing crosslinked protein crystals according to claim 73, wherein said crosslinking agent is selected from the group consisting of: glutaraldehyde, succinaldehyde, octanedialdehyde and glyoxal.

### Claim 76 (depends on 73)

The method for producing crosslinked protein crystals according to claim 73, wherein said crosslinking agent is selected from the group consisting of: halo-triazines, halo-pyrimidines, anhydrides of aliphatic or aromatic mono- or di-carboxylic acids, halides of aliphatic or aromatic mono- or di-carboxylic acids, N-methylol compounds, di-isocyanates, di-isothiocyanates and aziridines.

### Claim 77 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is an epoxide.

### Claim 78 (depends on 77)

The method for producing crosslinked protein crystals according to claim 77, wherein said epoxide is selected from the group consisting of: neopentyl glycol diglycidyl ether, ethylene glycol diglycidyl ether, di-epoxides, tri-epoxides and tetra-epoxides.

### Claim 79 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is 0.0076% to 0.5% glutaraldehyde and wherein the conditions sufficient to induce crosslinking include reacting protein crystals with a crosslinking agent for a period of time between about 3 minutes and about 120 minutes.

### Claim 80 (depends on 79)

The method for producing crosslinked protein crystals according to claim 79, wherein said crosslinking agent is 0.005% glutaraldehyde and wherein the conditions sufficient to induce crosslinking include reacting protein crystals with a crosslinking agent for a period of time between about 10 minutes and about 30 minutes.

### Claim 81 (depends on 79)

The method for producing crosslinked protein crystals according to claim 79 wherein, prior to reaction with said protein crystals, said glutaraldehyde is pretreated by incubation at 60° C. with a buffer for 1 hour.

### Claim 82 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is 0.01% to 1% glyoxal and wherein the conditions sufficient to induce crosslinking include reacting protein crystals with a crosslinking agent for a period of time between about 30 minutes and about 60 minutes.

### Claim 83 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is 0.05% to 1% octanedialdehyde and wherein the conditions sufficient to induce crosslinking include reacting protein crystals with a crosslinking agent for a period of time between about 30 minutes and about 16 hours.

### Claim 84 (depends on 83)

The method for producing crosslinked protein crystals according to claim 83, wherein said crosslinking agent is 1% octanedialdehyde and wherein the conditions sufficient to induce crosslinking include reacting protein crystals with a crosslinking agent for a period of time between about 1 hour and about 3 hours.

### Claim 85 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is 1% succinaldehyde and wherein the conditions sufficient to induce crosslinking include reacting protein crystals with a crosslinking agent for a period of time between about 30 minutes and about 3 hours.

### Claim 86 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said first crosslinking agent is 0.01% to 4% epoxide and said second crosslinking agent is 0.1% to 0.2% glutaraldehyde and wherein the conditions sufficient to induce crosslinking include reacting said protein crystals with said first crosslinking agent for a period of time between about 1 hour and about 72 hours and reacting said protein crystals with said second crosslinking agent for a period of time between about 1 hour and about 5 hours.

### Claim 87 (depends on 86)

The method for producing crosslinked protein crystals according to claim 86, wherein said first crosslinking agent is 0.01% epoxide and said second crosslinking agent is 0.1% glutaraldehyde and wherein the conditions sufficient to induce crosslinking include reacting said protein crystals with said first crosslinking agent for about 5 hours and reacting said protein crystals with said second crosslinking agent for about 1.5 hours.

### Claim 88 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said protein is an enzyme.

### Claim 89 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said crosslinking agent is a reversible crosslinking agent.

### Claim 90 (depends on 89)

The method for producing crosslinked protein crystals according to claim 89, wherein said reversible crosslinking agent is a disulfide crosslinking agent.

### Claim 91 (depends on 90)

The method for producing crosslinked protein crystals according to claim 90, wherein said disulfide crosslinking agent is a homobifunctional crosslinking agent or a heterobifunctional crosslinking agent.

### Claim 92 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said protein is an enzyme.

### Claim 93 (depends on 92)

The method for producing crosslinked protein crystals according to claim 92, wherein said enzyme is selected from the group consisting of hydrolases, isomerases, lyases, ligases, transferases and oxidoreductases.

### Claim 94 (depends on 93)

The method for producing crosslinked protein crystals according to claim 93, wherein said enzyme is from the group consisting of proteases, amylases, cellulases, lipases and oxidases.

### Claim 95 (depends on 66, 67, 68)

The method for producing crosslinked protein crystals according to any one of claims 66, 67 or 68, wherein said protein is selected from the group consisting of therapeutic proteins, cleaning agent proteins, personal care proteins, veterinary proteins, food proteins, feed proteins, diagnostic proteins and decontamination proteins.

### Claim 96 (depends on 95)

The method for producing crosslinked protein crystals according to claim 95, wherein said protein is selected from the group consisting of hormones, antibodies, inhibitors, growth factors, trophic factors, cytokines, lymphokines, growth hormones, nerve growth hormones, bone morphogenic proteins and toxoids.

### Claim 97 (depends on 96)

The method for producing crosslinked protein crystals according to claim 96, wherein said protein is selected from the group consisting of insulin, amylin, erythropoietin, Factor VIII, TPA, dornase-α, α-1-antitripsin, urease, fertility hormones, FSH, LSH, postridical hormones, tetanus toxoid and diptheria toxoid.
